MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Abbott Laboratories

Fechado

SetorSaúde

128.47 1.01

Visão Geral

Variação de preço das ações

24h

Atual

Mín

128.47

Máximo

129.22

Indicadores-chave

By Trading Economics

Rendimento

454M

1.8B

Vendas

784M

11B

P/E

Médio do Setor

16.484

36.442

EPS

1.26

Rendimento de Dividendos

1.75

Margem de lucro

15.967

Funcionários

114,000

EBITDA

383M

3B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+14.07% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

1.75%

3.00%

Próxima data de dividendos

17 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-1B

229B

Abertura anterior

127.46

Fecho anterior

128.47

Sentimento de Notícias

By Acuity

57%

43%

296 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Abbott Laboratories Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de out. de 2025, 12:02 UTC

Ganhos

Abbott Labs Posts Higher 3Q Sales, Reaffirms Outlook

17 de jul. de 2025, 12:10 UTC

Ganhos

Abbott Labs Pares Outlook, Logs 2Q Profit Gains

15 de out. de 2025, 16:15 UTC

Ganhos

Abbott Stock Drops Despite Earnings. Baby-Formula Sales Took a Hit. -- Barrons.com

15 de out. de 2025, 12:25 UTC

Ganhos

Abbott Posts Solid Earnings, Adult Nutrition Drives Sales. The Stock Drops Anyway. -- Barrons.com

15 de out. de 2025, 11:32 UTC

Ganhos

Abbott Labs Still Sees 2025 Organic Sales Up 6%-7% Including Covid-19 Testing-Related Sales >ABT

15 de out. de 2025, 11:32 UTC

Ganhos

Abbott Labs Still Sees 2025 Organic Sales Up 7.5%-8% Excluding Covid-19 Testing-Related Sales >ABT

15 de out. de 2025, 11:31 UTC

Ganhos

Abbott Labs Sees 2025 Adj EPS $5.12-Adj EPS $5.18 >ABT

15 de out. de 2025, 11:30 UTC

Ganhos

Abbott Labs 3Q Adjusted Operating Margin 23% >ABT

15 de out. de 2025, 11:30 UTC

Ganhos

Abbott Labs Reaffirms Full-Year Guidance >ABT

15 de out. de 2025, 11:30 UTC

Ganhos

Abbott Labs 3Q Organic Sales Growth Up 5.5% >ABT

15 de out. de 2025, 11:30 UTC

Ganhos

Abbott Labs 3Q Sales $11.37B >ABT

15 de out. de 2025, 11:30 UTC

Ganhos

Abbott Labs 3Q Adj EPS $1.30 >ABT

15 de out. de 2025, 11:30 UTC

Ganhos

Abbott Labs 3Q Net $1.64B >ABT

15 de out. de 2025, 11:30 UTC

Ganhos

Abbott Labs 3Q EPS 94c >ABT

11 de out. de 2025, 00:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Why Biotech May Be Back -- Barrons.com

17 de jul. de 2025, 13:14 UTC

Ganhos

Abbott Labs Stock Falls After Earnings. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17 de jul. de 2025, 12:16 UTC

Ganhos

Abbott Labs Stock Dives After Earnings Miss. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17 de jul. de 2025, 11:32 UTC

Ganhos

Abbott Labs Sees 3Q Adj EPS $1.28-Adj EPS $1.32 >ABT

17 de jul. de 2025, 11:32 UTC

Ganhos

Abbott Labs: See Momentum Carrying Into 2026 >ABT

17 de jul. de 2025, 11:31 UTC

Ganhos

Abbott Labs Sees 2025 Organic Sales Up 7.5%-8%, Excluding Covid-19 Testing-Related Sales >ABT

17 de jul. de 2025, 11:30 UTC

Ganhos

Abbott Labs 2Q Organic Sales Rose 6.9% >ABT

17 de jul. de 2025, 11:30 UTC

Ganhos

Abbott Labs 2Q Adjusted Operating Margin 22.9% >ABT

17 de jul. de 2025, 11:30 UTC

Ganhos

Abbott Labs 2Q Adjusted Gross Margin 57% >ABT

17 de jul. de 2025, 11:30 UTC

Ganhos

Abbott Labs 2Q Organic Sales Growth Up 6.9% >ABT

17 de jul. de 2025, 11:30 UTC

Ganhos

Abbott Labs 2Q Sales $11.14B >ABT

17 de jul. de 2025, 11:30 UTC

Ganhos

Abbott Labs 2Q Net $1.78B >ABT

17 de jul. de 2025, 11:30 UTC

Ganhos

Abbott Labs 2Q Adj EPS $1.26 >ABT

17 de jul. de 2025, 11:30 UTC

Ganhos

Abbott Labs Sees FY Adj EPS $5.10-Adj EPS $5.20 >ABT

17 de jul. de 2025, 11:30 UTC

Ganhos

Abbott Labs 2Q EPS $1.01 >ABT

17 de jul. de 2025, 09:08 UTC

Ações em Alta

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

Comparação entre Pares

Variação de preço

Abbott Laboratories Previsão

Preço-alvo

By TipRanks

14.07% parte superior

Previsão para 12 meses

Média 146.63 USD  14.07%

Máximo 162 USD

Mínimo 136 USD

Com base em 20 analistas de Wall Street que oferecem metas de preço de 12 meses para Abbott Laboratories - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

20 ratings

18

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

132.82 / 134.43Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Neutral Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

296 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
help-icon Live chat